Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction

Transplant Infectious Disease

Volumn 14, Issue 4, 2012, Pages 440-443

  Van der Elst, K C M ^a   Bruggemann R J M ^b   Rodgers, M G G ^a   Alffenaar, J W C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Caspofungin; Hepatic dysfunction; Invasive aspergillosis; Liver transplantation; Plasma concentration

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CASPOFUNGIN; GAMMA GLUTAMYLTRANSFERASE; MYCOPHENOLIC ACID; TACROLIMUS; VORICONAZOLE;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CASE REPORT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; FUNGUS ISOLATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LUNG ASPERGILLOSIS; MAINTENANCE DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RESPIRATORY FAILURE; SIDE EFFECT; THORAX RADIOGRAPHY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; FEMALE; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84865172168     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00716.x     Document Type: Article

References (17)

1. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
2. Wang JL, Chang CH, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother 2010; 54: 2409-2419.
3. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
4. Viscoli C, Herbrecht R, Akan H, et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64: 1274-1281.
5. Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45: 1227-1233.
6. Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48: 815-823.
7. Cancidas product information, 24-10-2001 (Accessed January 10, 2011). Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000379/human_med_000684.jsp&mid=WC0b01ac058001d124.
8. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888-2897.
9. Betts RF, Nucci M, Talwar D, et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-1684.
10. Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60: 363-369.
11. Safdar A, Rodriguez G, Rolston KV, et al. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 157-164.
12. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011; 71: 11-41.
13. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
14. Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: an echinocandin antifungal agent. Clin Ther 2002; 24: 351-377.
15. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 2010; 54: 2497-2506.
16. Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739-745.
17. Mistry GC, Migoya E, Deutsch PJ, et al. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol 2007; 47: 951-961.